MX2022000283A - Peptidos mimetidos de bcl9 modificados. - Google Patents

Peptidos mimetidos de bcl9 modificados.

Info

Publication number
MX2022000283A
MX2022000283A MX2022000283A MX2022000283A MX2022000283A MX 2022000283 A MX2022000283 A MX 2022000283A MX 2022000283 A MX2022000283 A MX 2022000283A MX 2022000283 A MX2022000283 A MX 2022000283A MX 2022000283 A MX2022000283 A MX 2022000283A
Authority
MX
Mexico
Prior art keywords
bcl9
mimetic peptides
modified
region
mimetic
Prior art date
Application number
MX2022000283A
Other languages
English (en)
Inventor
Barry Jay Kappel
Gene Merutka
Jimmy Andrew Rotolo
Erin E Gallagher
Original Assignee
Sapience Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics Inc filed Critical Sapience Therapeutics Inc
Publication of MX2022000283A publication Critical patent/MX2022000283A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a péptidos miméticos de BCL9 que tienen una región del dominio 2 de homología (HD2) a-helicoidal modificada y, opcionalmente, una región de penetración celular, composiciones que comprenden los péptidos miméticos de BCL9 y métodos para inhibir la proliferación y/o promover la citotoxicidad en una célula neoplásica usando los péptidos miméticos de BCL9.
MX2022000283A 2019-07-05 2020-07-06 Peptidos mimetidos de bcl9 modificados. MX2022000283A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962870938P 2019-07-05 2019-07-05
PCT/US2020/040889 WO2021007158A1 (en) 2019-07-05 2020-07-06 Modified bcl9 mimetic peptides

Publications (1)

Publication Number Publication Date
MX2022000283A true MX2022000283A (es) 2022-09-23

Family

ID=74114087

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000283A MX2022000283A (es) 2019-07-05 2020-07-06 Peptidos mimetidos de bcl9 modificados.

Country Status (11)

Country Link
US (1) US20220275036A1 (es)
EP (1) EP3994160A4 (es)
JP (1) JP2022538686A (es)
KR (1) KR20220030992A (es)
CN (1) CN114144424A (es)
AU (1) AU2020311873B2 (es)
BR (1) BR112022000004A2 (es)
CA (1) CA3144458A1 (es)
IL (1) IL289460A (es)
MX (1) MX2022000283A (es)
WO (1) WO2021007158A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833171C (en) * 2011-04-15 2021-08-31 Loren D. Walensky Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9

Also Published As

Publication number Publication date
CA3144458A1 (en) 2021-01-14
WO2021007158A1 (en) 2021-01-14
US20220275036A1 (en) 2022-09-01
AU2020311873A1 (en) 2022-01-27
AU2020311873B2 (en) 2024-03-21
KR20220030992A (ko) 2022-03-11
IL289460A (en) 2022-02-01
JP2022538686A (ja) 2022-09-05
CN114144424A (zh) 2022-03-04
EP3994160A1 (en) 2022-05-11
BR112022000004A2 (pt) 2022-03-22
EP3994160A4 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
MX2020012028A (es) Metodos y composiciones para tratar el cancer.
MX2020008542A (es) Composiciones y métodos para el suministro de proteínas membranales.
NZ765759A (en) Atf5 peptide variants and uses thereof
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
ZA201908445B (en) Recombinant adenoviruses carrying transgenes
MX2019011592A (es) Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
MX2022006188A (es) Variantes del vector viral adenoasociado.
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
PH12021551101A1 (en) Immunogenic peptides with improved oxidoreductase motifs
MY192295A (en) Peptides and methods for the treatment of diabetes
ZA202106602B (en) Claudin 6 antibodies and uses thereof
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
MX2021007221A (es) Factor i del complemento y cofactor del factor i del complemento, vectores que realizan codificacion para estos y uso terapeutico.
MX2019006133A (es) Copolimeros y su uso en composiciones de agentes de limpieza.
MX2019013210A (es) Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2022002337A (es) Polipéptidos de tff2 modificados.
MX2018005467A (es) Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas.
MX2020008231A (es) Composiciones de edb que se dirigen a il-12.
MX2021014949A (es) Recubrimientos resistentes a la incrustación biológica y métodos para elaborar y usar los mismos.
MX2022011077A (es) Variantes de transglutaminasa.
MX2022013840A (es) Polipéptidos de unión a pd-1 canina y usos de los mismos.
MX2022001518A (es) Composiciones que comprenden enzimas digestivas.
MX2022000283A (es) Peptidos mimetidos de bcl9 modificados.